藥康生物(688046.SH):與靈康生物共同開發基因編輯豬品系並探索下遊應用
格隆匯7月18日丨藥康生物(688046.SH)在投資者互動平臺表示,公司於2024年戰略入股江蘇靈康生物科技有限公司,並於2025年完成新一輪增資,目前共持有靈康生物33.34%股權。靈康生物專業從事實驗豬的疾病動物模型研發、基因編輯動物開發、動物實驗服務、異種器官移植研究等業務,擁有五指山小型豬、巴馬小型豬、長白豬等豐富品系。公司將基於紮實底層技術和通用技術平臺,與靈康生物共同開發基因編輯豬品系並探索下遊應用。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.